Business Wire

CA-JABIL

23.9.2019 14:50:11 CEST | Business Wire | Press release

Share
Jabil Photonics to Demonstrate Coherent SiP based 100G/200G CFP2-DCO Product at ECOC 2019

Jabil (NYSE: JBL) today announced that its Photonics business unit, a leading provider of customized end-to-end design, manufacturing and test solutions for optical communication products, will be demonstrating its coherent 100G/200G CFP2-DCO module this week at the ECOC Exhibition (Hall 4, Booth 498) in Dublin, Ireland.

Jabil’s CFP2-DCO is a hot-pluggable module designed to support single-wavelength data coherent transmission at 100Gbps using DP-QPSK and 200Gbps using DP-16QAM modulations. The CFP2-DCO is designed for DWDM networks ranging from metro and data-center interconnect (DCI) to long-haul applications, as well as 100Gbps point-to-point (P2P) coherent solutions for unamplified links in 5G and cable access networks up to 80km.

Powered by Elenion Technologies’ next generation Silicon Photonics (SiP) coherent engine, the Jabil Photonics CFP2-DCO sets a new standard for price-performance. The module incorporates an ultra-narrow linewidth external cavity micro-ITLA laser with gridless DWDM wavelength capability for tuning across the extended C-Band, and a low power coherent Digital Signal Processor (DSPs) using advanced 16-nm CMOS technology.

“As the pace of optical networking innovation and the surge of bandwidth demand in communication networks continues to accelerate, the ecosystem needs players that can quickly enable volume manufacturing and simplify sourcing models,” said Stefano Schiavoni, vice president and GM of Jabil’s Photonics business unit. “The release of our CFP2-DCO product represents a significant industry milestone by delivering a vertically integrated solution at the lowest cost structure. Unlike traditional build-to-print contract manufacturers, Jabil leverages its advanced design capabilities, operational excellence and world-class supply chain to meet the increasingly competitive requirements of our customers.”

“We are pleased with the opportunity to partner with Jabil Photonics to manufacture our sophisticated SiP coherent optical engines together with the CFP2-DCO in Jabil’s precision optical manufacturing line,” said Larry Schwerin, president and CEO of Elenion Technologies.

The CFP2-DCO will be Jabil’s first product launched under the “Jabil Photonics” brand which replaces the former “Jabil AOC Technologies” brand. The new branding reflects Jabil’s end-to-end manufacturing and supply chain capabilities in the area of photonics. In addition to the product line expansion with the Jabil Photonics CFP2-DCO, Jabil is growing its investment in the optical segment with the expansion of its Penang, Malaysia, production facility with a focus on Optical Manufacturing Services (OMS) as well as Jabil Photonics components.

About Jabil

Jabil (NYSE: JBL) is a manufacturing solutions provider that delivers comprehensive design, manufacturing, supply chain and product management services. Leveraging the power of over 200,000 people across 100 sites strategically located around the world, Jabil simplifies complexity and delivers value in a broad range of industries, enabling innovation, growth and customer success. For more information, visit jabil.com .

About Jabil Photonics

Jabil Photonics (formerly Jabil AOC Technologies) is a business unit of Jabil and a leading provider of comprehensive optical communication solutions with end-to-end optical design, manufacturing and advanced optical packaging capabilities across a full line of discrete optical components, integrated optical modules and complexed fiber-based boards. Jabil Photonics will be attending 2019 ECOC in Dublin, Ireland on Sept. 23 – Sept. 25. For more information, please contact: Chuck_sinha@jabil.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release

Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye